

**AMENDMENTS TO THE SPECIFICATION**

Please amend the second full paragraph on page 33 as follows:

In this embodiment, when the binding ligand is a nucleic acid, preferred compositions and techniques are outlined in WO 98/20162; WO 98/57159; WO 98/57158; WO 99/37819; WO 99/57319; and U.S. Ser. Nos. 09/135,183, and 60/105,875; and U.S. Patent Nos. No. 7,090,804 and 6,942,771, all of which are hereby expressly incorporated by reference.